Literature DB >> 30790581

A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.

Aman P Singh1, Dhaval K Shah2.   

Abstract

Here, we have developed a cell-level systems PK-PD model to characterize the bystander effect of antibody-drug conjugates (ADCs). Cytotoxicity data generated following incubation of Trastuzumab-vc-MMAE in cocultures of high HER2-expressing N87 and low HER2-expressing GFP-MCF7 cells were used to build the model. Single-cell PK model for ADC was used to characterize the PK of trastuzumab-vc-MMAE and released MMAE in N87 and GFP-MCF7 cells. The 2 cell-level PK models were mechanistically integrated to mimic the coculture condition. MMAE-induced intracellular occupancy of tubulin was used to drive the efficacy of ADC, and improvement in the tubulin occupancy of GFP-MCF7 cells in the presence of N87 cells was used to drive the bystander effect of trastuzumab-vc-MMAE. The "dual" cell-level PK-PD model was able to capture the observed data reasonably well. It was found that similar and high occupancy of tubulin by MMAE was required to achieve the cytotoxic effect in each cell line. In addition, estimated model parameters suggested that ∼60% improvement in the tubulin occupancy was required to attain half of the maximum bystander killing effect by the ADC. The presented model provides foundation for in vivo systems PK-PD model to characterize and predict the bystander effect of ADCs.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibody-drug conjugates; bystander effect; cellular disposition; microtubule inhibitors; single-cell PK-PD model; trastuzumab-vc-MMAE

Year:  2019        PMID: 30790581      PMCID: PMC6591081          DOI: 10.1016/j.xphs.2019.01.034

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  35 in total

Review 1.  Targeted cancer therapy--are the days of systemic chemotherapy numbered?

Authors:  Won Duk Joo; Irene Visintin; Gil Mor
Journal:  Maturitas       Date:  2013-09-20       Impact factor: 4.342

2.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.

Authors:  Hyesil Seol; Hyun Ju Lee; Yoomi Choi; Hee Eun Lee; Yu Jung Kim; Jee Hyun Kim; Eunyoung Kang; Sung-Won Kim; So Yeon Park
Journal:  Mod Pathol       Date:  2012-03-02       Impact factor: 7.842

Review 3.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

5.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Authors:  Dhaval K Shah; Nahor Haddish-Berhane; Alison Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-15       Impact factor: 2.745

6.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Authors:  Yelena V Kovtun; Charlene A Audette; Yumei Ye; Hongsheng Xie; Mary F Ruberti; Sara J Phinney; Barbara A Leece; Thomas Chittenden; Walter A Blättler; Victor S Goldmacher
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

7.  Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

Authors:  Anthony W Tolcher; Leonel Ochoa; Lisa A Hammond; Amita Patnaik; Tam Edwards; Chris Takimoto; Lon Smith; Johann de Bono; Garry Schwartz; Theresa Mays; Zdenka L Jonak; Randall Johnson; Mark DeWitte; Helen Martino; Charlene Audette; Kate Maes; Ravi V J Chari; John M Lambert; Eric K Rowinsky
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

Review 8.  Molecular profiling for breast cancer: a comprehensive review.

Authors:  Muaiad Kittaneh; Alberto J Montero; Stefan Glück
Journal:  Biomark Cancer       Date:  2013-10-29

9.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis.

Authors:  Sabrina L Spencer; Suzanne Gaudet; John G Albeck; John M Burke; Peter K Sorger
Journal:  Nature       Date:  2009-04-12       Impact factor: 49.962

10.  American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.

Authors:  Karen Thudium; Sanela Bilic; Douglas Leipold; William Mallet; Surinder Kaur; Bernd Meibohm; Hans Erickson; Jay Tibbitts; Hong Zhao; Manish Gupta
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

View more
  6 in total

1.  Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect.

Authors:  Aman P Singh; Gail M Seigel; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Hsuan-Ping Cheng; Dhaval K Shah
Journal:  J Pharmacol Exp Ther       Date:  2020-04-09       Impact factor: 4.030

2.  An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.

Authors:  Bruna Menezes; Cornelius Cilliers; Timothy Wessler; Greg M Thurber; Jennifer J Linderman
Journal:  AAPS J       Date:  2020-01-15       Impact factor: 4.009

3.  A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs.

Authors:  Aman P Singh; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Dhaval K Shah
Journal:  Pharmaceutics       Date:  2019-02-25       Impact factor: 6.321

4.  Bivalent EGFR-Targeting DARPin-MMAE Conjugates.

Authors:  Lennard Karsten; Nils Janson; Vadim Le Joncour; Sarfaraz Alam; Benjamin Müller; Jayendrakishore Tanjore Ramanathan; Pirjo Laakkonen; Norbert Sewald; Kristian M Müller
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

Review 5.  Antibody drug conjugate: the "biological missile" for targeted cancer therapy.

Authors:  Zhiwen Fu; Shijun Li; Sifei Han; Chen Shi; Yu Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-03-22

Review 6.  Development of and insights from systems pharmacology models of antibody-drug conjugates.

Authors:  Inez Lam; Venkatesh Pilla Reddy; Kathryn Ball; Rosalinda H Arends; Feilim Mac Gabhann
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-07-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.